NYU Medical Center has entered into a strategic alliance with Siemens Medical Solutions. The cornerstone of the alliance is a seven-year agreement that makes Siemens the exclusive supplier of the center's radiology imaging. The commercial value of the
NYU Medical Center has entered into a strategic alliance with Siemens Medical Solutions. The cornerstone of the alliance is a seven-year agreement that makes Siemens the exclusive supplier of the center's radiology imaging. The commercial value of the agreement will exceed $110 million, according to the company. The agreement covers approximately 100 advanced imaging systems, including a high-resolution research 7T MR scanner. Also included will be CTs, PET scanners, mammography, digital x-ray, and ultrasound equipment, as well as PACS. Due to the size and scope of the agreement, NYU and Siemens expect it will take four years to install all of the equipment and systems.
Another key aspect of the alliance is the commitment from both partners to MR imaging research. NYU plans to construct a new MR research facility near its midtown campus in Manhattan to house some of the new equipment, including the new 7T system, which will require a special room reinforced by some 300 tons of steel. Siemens will also install two 3T scanners dedicated to imaging research, particularly of the human brain, liver, kidneys, and prostate.
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.